A new angle for glp-1 receptor agonist: The medical economics argument

Willy Marcos Valencia, Hermes Jose Florez

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are relatively new medications for diabetes that offer a weight-loss profile that can be considered desirable for patients with both type 2 diabetes (T2D) and obesity. GLP-1 RA are effective in combination with insulin, and even slightly superior or at least equal to short-acting insulin in T2D; however, since they work in the incretin system, they may not be effective in long-standing disease. Additionally, only recently have publications reported their cardiovascular safety, and there is limited evidence for long-term effectiveness. The work presented by Huetson et al. offers a much needed perspective through a medical economic model for the long term cost-effectiveness of GLP-1 RA. The authors found benefits in quality-adjusted life years and reduced lifetime healthcare costs. While there are a few limitations, this study contributes to the understanding of these agents and their impact on the epidemics of obesity in T2D, where weight management is no longer an option, but an essential component of the diabetes plan of care.

Original languageEnglish (US)
Pages (from-to)1029-1031
Number of pages3
JournalJournal of Medical Economics
Volume18
Issue number12
DOIs
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Health Policy

Fingerprint

Dive into the research topics of 'A new angle for glp-1 receptor agonist: The medical economics argument'. Together they form a unique fingerprint.

Cite this